Paragon Therapeutics spinning out another company, Damora Therapeutics, focused on mutCALR - a buzzy target for myelofibrosis and related diseases. $INCY has one, with data coming at ASH.
Damora coming public via merger with $GLTO + $285M PIPE.
https://t.co/Ma0nR4TXiT